YD Bio Ltd Dossier - Source-backed chat

YD Bio Ltd

YDESNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.25

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.42Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $525.6M

Enterprise Value $519.6M

Shares Outstanding 66.7M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

YD Bio Ltd (YDES) is transitioning from a single-asset biotechnology model to an integrated oncology and regenerative medicine platform. While the company achieved a 17% increase in net revenue to $596.8K in FY2025 and maintains a debt-free balance sheet with $6.0M in cash, its net loss widened significantly to $8.3M due to rising operational, R&D, and restructuring costs. The company's future growth is highly dependent on the successful execution of its non-binding MOU to merge with EG BioMed and the clinical advancement of its Limbal Stem Cell and exosome platforms. Given the substantial going concern risks, high dilution from warrant exercises, and early-stage commercial footprint, a Hold recommendation is warranted until definitive merger agreements are finalized and clinical milestones are achieved.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The merger with EG BioMed falls through, or faces severe regulatory delays. The FDA raises concerns regarding the IND submissions for the ocular platforms, delaying clinical trials. Cash reserves are depleted rapidly, forcing highly dilutive equity raises at depressed valuations, and the stock price continues its downward trend toward historical lows.

Base CaseCentral scenario

The company successfully finalizes its merger with EG BioMed in late 2026, integrating DNA methylation-based cancer diagnostics with its clinical services. Preclinical studies for Dry Eye Disease and AMD progress as planned, leading to IND submissions. Revenue continues to grow at a moderate double-digit rate, but cash burn remains high, requiring additional dilutive equity financing.

Bull CaseUpside scenario

YD Bio is transitioning from platform validation to clinical and commercial execution, supported by its newly established 'Taiwan-U.S. Dual-Core' regulatory platform with YC Biotech and the launch of its nationwide EG Telehealth Platform in 44 U.S. states to accelerate early cancer detection commercialization.

Scenarios reflect our research view at the research date.

Key Investment Merits

Integrated platform combining early cancer detection (DNA methylation) with advanced therapeutics.
Strategic non-binding MOU to merge with EG BioMed to create a data-driven oncology ecosystem.
Debt-free balance sheet with $6.0M in cash as of December 31, 2025.
Completed CMC development and filed FDA Drug Master Files (DMFs) for Limbal Stem Cell and exosome platforms.

Key Investment Risks

Substantial doubt exists regarding the company's ability to continue as a going concern.
Widening net losses ($8.3M in FY2025 vs $1.4M in FY2024) driven by high G&A and R&D expenses.
Significant dilution risk from the registration of over 11.4 million ordinary shares from warrant exercises.
High dependence on intellectual property licensed from third parties (e.g., EG BioMed License Agreements).

Thesis Invalidation Triggers

Termination or failure to consummate the proposed merger with EG BioMed.
FDA rejection or clinical hold on planned 2026 IND submissions.
Inability to secure additional financing, leading to severe liquidity constraints.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.